The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.

MLA

Monteiro, Isabel, et al. “The Ocrelizumab Wearing-off Phenomenon Is Associated with Reduced Immunomodulatory Response and Increased Neuroaxonal Damage in Multiple Sclerosis.” Journal of Neurology, vol. 271, no. 8, Aug. 2024, pp. 5012–24. EBSCOhost, https://doi.org/10.1007/s00415-024-12434-w.

APA

Monteiro, I., Nicolella, V., Fiorenza, M., Novarella, F., Carotenuto, A., Lanzillo, R., Mauriello, L., Scalia, G., Castaldo, G., Terracciano, D., Brescia Morra, V., & Moccia, M. (2024). The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis. Journal of Neurology, 271(8), 5012–5024. https://doi.org/10.1007/s00415-024-12434-w

Chicago

Monteiro, Isabel, Valerio Nicolella, Mariano Fiorenza, Federica Novarella, Antonio Carotenuto, Roberta Lanzillo, Lucia Mauriello, et al. 2024. “The Ocrelizumab Wearing-off Phenomenon Is Associated with Reduced Immunomodulatory Response and Increased Neuroaxonal Damage in Multiple Sclerosis.” Journal of Neurology 271 (8): 5012–24. doi:10.1007/s00415-024-12434-w.